GHRP-6

Growth Hormone Releasing Peptide-6

Rank#999
Growth HormoneNot ApprovedAnimalResearchSubQ

Popular for:Growth hormone release, appetite stimulation, gut motility

632

Total Studies

234

Human Studies

Animal

Evidence Level

Not Approved

FDA Status

Overview

GHRP-6 (Growth Hormone Releasing Peptide-6) is the original synthetic growth hormone releasing peptide, a hexapeptide first described in the 1980s. It strongly stimulates GH release through the ghrelin receptor and is known for producing significant appetite stimulation within 20-30 minutes of administration.

GHRP-6 has been extensively studied in clinical research and is one of the most well-characterized GHRPs in the literature. Its strong appetite-stimulating effects make it popular in research involving caloric intake and weight gain.

Mechanism of Action

GHRP-6 binds to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus, triggering GH release through both direct pituitary stimulation and suppression of somatostatin. It also stimulates ghrelin-like signaling in the gut and hypothalamus, which drives its pronounced appetite-stimulating effects.

Key Research Benefits

Strong, well-characterized GH release
Significant appetite stimulation (useful for bulking research)
Extensively studied in clinical literature
Synergistic with GHRH analogs
Researched for gastric motility and gut health effects

Clinical Evidence Summary

Research Pipeline

Preclinical
Animal
Phase I
Phase II
Phase III
Approved

632

Total Studies

234

Human Studies

Not FDA-approved. One of the most studied GHRPs in clinical literature. Research compound.

Key Studies / PubMed References

632 studies found on PubMed · showing top 25 by relevance

View all on PubMed

Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.

In Vitro

Zhao X, Pan K, Li R, et al. · Journal of nanobiotechnology · 2025

PMID: 41327290

Calorie restriction activates a gastric Notch-FOXO1 pathway to expand ghrelin cells.

In Vitro

McKimpson WM, Spiegel S, Mukhanova M, et al. · The Journal of cell biology · 2024

PMID: 38958606

Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.

Human Study

Berlanga-Acosta J, Cibrian D, Valiente-Mustelier J, et al. · Frontiers in pharmacology · 2024

PMID: 38873418

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

Review

Sinha DK, Balasubramanian A, Tatem AJ, et al. · Translational andrology and urology · 2020

PMID: 32257855

[D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle.

Review

Yu AP, Pei XM, Sin TK, et al. · Molecular and cellular endocrinology · 2015

PMID: 25450862

Side Effects & Safety

Intense hunger within 20-30 minutes
Elevated cortisol
Elevated prolactin
Water retention and bloating
Potential blood sugar fluctuations

Known Interactions

No curated interaction entry is live for GHRP-6 yet.

Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.

Frequently Asked Questions

Research Disclaimer

This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. GHRP-6 is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before making any health-related decisions. The studies referenced are linked to their original PubMed sources for verification.